Cybin announces four poster presentations at the 2023 american college of neuropsychopharmacology annual meeting including cyb003 phase 2 topline results

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced the presentation of four posters at the american college of neuropsychopharmacology (“acnp”) annual meeting taking place december 3-6, 2023, in tampa, florida. the data presented include topline data from its p.
CYBN Ratings Summary
CYBN Quant Ranking